Stephen Gordon, the Chief Financial Officer of TransMedics Group Inc (TMDX, Financial), sold 15,000 shares of the company on April 1, 2024, according to a recent SEC Filing. The transaction was executed at a price of $74.01 per share, resulting in a total sale amount of $1,110,150.
TransMedics Group Inc is a medical technology company that specializes in developing products for organ transplant therapy. The company's flagship product, the Organ Care System, is designed to preserve organ function and improve transplant outcomes.
Over the past year, the insider, Stephen Gordon, has sold a total of 56,903 shares and has not made any purchases of the company's stock.
The insider transaction history for TransMedics Group Inc shows a pattern of insider selling, with 28 insider sells and only 1 insider buy over the past year.
Shares of TransMedics Group Inc were trading at $74.01 on the day of the insider's recent sale, giving the company a market capitalization of $2.373 billion.
With the current share price and a GuruFocus Value of $197.07, TransMedics Group Inc has a price-to-GF-Value ratio of 0.38. According to GuruFocus, this suggests that the stock could be a Possible Value Trap, and investors should think twice before making an investment decision.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor related to the company's past performance, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
